Clinical Trials Browser

Phase NA × lenvatinib × 30 days × Clear all

NCT07535840 2026-04-17

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Phase NA Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular